Citius Oncology (CTOR) vs iBio (IBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
iBio (IBIO) has outperformed Citius Oncology (CTOR) over the past year, losing 23.8% versus a loss of 55.4%. iBio is the larger company by market cap ($56.4 million vs $53.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | IBIO |
|---|---|---|
| Share price | $0.5035 | $0.8001 |
| Market cap | $53.25M | $56.37M |
| 1-day change | -10.95% | -0.11% |
| YTD return | -49.65% | -58.54% |
| 1-year return | -55.44% | -23.80% |
| 5-year return | — | -99.76% |
| EPS (TTM) | $-0.48 | $-0.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $100.00K |
| Revenue growth (YoY) | — | -75.00% |
| Net income (latest FY) | $-24.76M | $-33.04M |
| Operating margin | — | -35141.00% |
| Net margin | — | -33044.00% |
| 52-week high | $1.83 | $3.82 |
| 52-week low | $0.491 | $0.68 |
| Distance from 52-week high | -72.49% | -79.05% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +694.44% | +611.16% |
| Average volume | 114.02K | 678.91K |
| Shares outstanding | 105.76M | 70.46M |
| Employees | — | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed CTOR by 31.6 percentage points over the past year.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
CTOR vs IBIO FAQ
Which is bigger, Citius Oncology or iBio?
iBio (IBIO) is larger, with a market capitalization of $56.37M compared with $53.25M for Citius Oncology (CTOR).
Which stock has performed better over the past year, CTOR or IBIO?
IBIO returned -23.80% over the past 12 months, compared with -55.44% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and iBio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.